WO1996009314A2 - Method for loading solid supports for nucleic acid synthesis - Google Patents

Method for loading solid supports for nucleic acid synthesis Download PDF

Info

Publication number
WO1996009314A2
WO1996009314A2 PCT/US1995/012196 US9512196W WO9609314A2 WO 1996009314 A2 WO1996009314 A2 WO 1996009314A2 US 9512196 W US9512196 W US 9512196W WO 9609314 A2 WO9609314 A2 WO 9609314A2
Authority
WO
WIPO (PCT)
Prior art keywords
nucleoside
loading
cpg
diisopropylcarbodiimide
solid support
Prior art date
Application number
PCT/US1995/012196
Other languages
French (fr)
Other versions
WO1996009314A3 (en
Inventor
Nandkumar Bhongle
Jin-Yan Tang
Original Assignee
Hybridon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon, Inc. filed Critical Hybridon, Inc.
Priority to AU37242/95A priority Critical patent/AU3724295A/en
Publication of WO1996009314A2 publication Critical patent/WO1996009314A2/en
Publication of WO1996009314A3 publication Critical patent/WO1996009314A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Definitions

  • This invention relates to the field of oligonucleotide synthesis, and, more particularly, to methods of loading mononucleosides on a solid support.
  • oligonucleotide methylphosphonates using phosphoramidite chemistry Connolly et al., Biochemistry 23, 3443 (1984), discloses synthesis of oligonucleotide phosphorothioates using phosphoramidite chemistry.
  • Jager et al., Biochemistry 27, 7237 (1988) discloses synthesis of oligonucleotide phosphoramidates using phosphoramidite chemistry.
  • Solid phase synthesis of ohgonucleotides by the foregoing methods involves the same generalized protocol. Briefly, this approach comprises anchoring the 3'- most nucleoside to a solid support functionalized with amino and or hydroxyl moieties and subsequently adding the additional nucleosides in stepwise fashion. Desired internucleoside linkages are formed between the 3' functional group of the incoming nucleoside and the 5' hydroxyl group of the 5'-most nucleoside of the nascent, support-bound oligonucleotide. Oligonucleotide synthesis generally begins with coupling, or "loading," of the 3 '-most nucleoside of the desired oligonucleotide to a functionalized solid phase support.
  • the functionalized support has a plurality of long chain alkyl amines (LCAA) on the surface that serve as sites for nucleoside coupling.
  • LCAA long chain alkyl amines
  • CPG Controlled pore glass
  • CPG supports are generally loaded by attaching a nucleoside-3'-succinate to the support through the succinyl group via an amide bond.
  • DCC dicyclohexylcarbo-diimide
  • Activation was accomplished by converting the nucleoside-3'-succinate into the symmetrical anhydride (Sproat and Gait, in Oligonucleotide Synthesis: a Practical
  • DCC and 1-hydoxybenzotriazole (HOBT) (used in equimolar amounts in a 14:1 dichloromethane/dimethylformamide solvent) resulted in higher loading densities than when DCC was used alone.
  • the use of DCC suffers from a number of disadvantages, however. First, DCC is highly toxic. Second, loading was tedious and gave only moderate yields (50-75%). Third, the coupling reactions were lengthy, requiring 3-4 d to make the activated succinates and an additional 4-7 d to couple them to the CPG. And finally, loading values were quite variable, and optimum loading of 30-40 ⁇ mol/g was not always obtained.
  • the present invention comprises new and improved methods of loading nucleosides onto a solid support for solid phase oligonucleotide synthesis.
  • the methods of the present invention provide several advantages over prior art methods. First, they are more cost efficient. Cheaper, more efficient catalysts and activators used in the present invention result in cost savings as lesser amounts of both catalyst and mononucleoside reactant are required. Savings of approximately 43% have been observed for loading densities of about 70-80 ⁇ mol/g. Second, we are able to eliminate pyridine as a solvent, which not only effects cost savings, but improves the safety of the process, both to the worker and to the environment.
  • DIC diisopropylcarbodiimide
  • HOBT 1-hydoxybenzotriazole
  • DIC 1-hydoxybenzotriazole
  • HOBT acts more efficiently and economically than other compounds such as N-hydroxysuccinimide (NHS), paratoluenesulfonic acid (pTSA), and trifluoroacteic acid (TFA).
  • NHS N-hydroxysuccinimide
  • pTSA paratoluenesulfonic acid
  • TFA trifluoroacteic acid
  • Loading densities approaching 120 ⁇ mol/g on controlled pore glass (CPG) solid support are readily obtained. Higher loading densities are also observed on other solid supports such as the "TENTAGEL” (Rapp Polymere) and "HLP" (ABI).
  • Nitrobenzotriazole acts as efficiently as HOBT, but is somewhat more expensive.
  • a method is presented for loading a non-linker-attached nucleoside (i.e., a nucleoside having a free 3' hydroxyl group) onto a solid support bearing a linker groug, e.g., a succinyl moiety.
  • a solid support to which a linker has been attached is loaded by contacting it with a nucleoside having a free 3' hydroxyl group in the presence of DIC and HOBT.
  • pyridine is eliminated as a solvent.
  • Pyridine has generally been used in the loading process as a solvent and to dissolve and wash away all catalyst, unreacted starting materials, and reaction by-products. Because of pyridine's toxicity, its elimination from the loading process increases the safety of the process. In addition, fewer environmentally hazardous wastes are produced. We have found that acetonitrile can be used in place of pyridine without affecting loading efficiencies. Cost savings are also thereby realized.
  • Another benefit provided by the methods of the present invention is the ability to adjust loading densities to any desired level, up to the maximum possible empirical value obtainable under optimal conditions. This is useful because equipment limitations (and/or other factors) may restrict the degree of loading to values substantially less than the empirical maximum.
  • the present methods can be used to load any nucleoside onto any functionalized solid support.
  • the nucleoside may comprise any unmodified base
  • the present invention comprises new methods for loading mononucleosides on a solid support.
  • loading refers to the chemical linkage of a nucleoside (which will be the 3'-most nucleoside of the oligonucleotide to be synthesized) to a functional group on a solid support. The degree of loading is expressed in ⁇ mol monomer/g solid support.
  • a “functional group” is a chemical moiety, such as an amino or hydroxyl moiety, capable of being joined to a nucleoside either directly or via a linker.
  • a “functionalized support” is a support having such functional groups.
  • the new methods disclosed herein are also significantly less hazardous for the worker and safer for the environment.
  • Pyridine is currently used as a reaction solvent and, alone or in combination with other solvents, to wash away unreacted reactants, catalyst, and unwanted reaction by-products.
  • the amount of pyridine can be reduced to about 5% in acetonitrile or eliminated completely. Because pyridine is toxic and has an obnoxious odor, the present methods are less hazardous than the prior art methods.
  • the present methods also require lesser amounts of reagents, resulting in lesser costs and amounts of waste.
  • column loading densities in the range of about 70-80 ⁇ mol/g can be attained using less than about 3 x 10° mol of nucleoside per 25 g of CPG.
  • the current methods provide additional cost savings by these means as well.
  • savings of about 43% are realized with the new methods for loading densities in the range of about 70-80 ⁇ mol/g.
  • the present invention provides methods of loading a functionalized solid support for oligonucleoside synthesis comprising contacting the functionalized solid support with a solvent, diisopropylcarbodiimide, and a nucleoside having a 3' linker group attached at a pH of less than 7.0.
  • diisopropylcarbodiimide is used as an activator for the acid catalyzed loading of nucleoside-3 '-succinates.
  • the activator forms an intermediate with the terminal carboxylic acid moiety of the nucleoside-3'-succinate, rendering it susceptible to nucleophilic attack by a support- bound amino functional group.
  • DIC in the presence of 1-hydroxybenzotirazole (HOBT) is more effective than DEC at activating the succinyl carboxylic acid moiety.
  • HOBT is used to catalyze DIC activated loading.
  • pyridine as a solvent
  • pTSA paratoluenesulfonic acid
  • TFA trifluoroacetic acid
  • Our experiments demonstrate that the use of HOBT results in loading densities ranging from 30 to 100% greater than those attained using NHS, pTSA, and TFA.
  • the amount of HOBT is not critical; it should be sufficient to catalyze the reaction.
  • about 0.08 to about 0.16 g HOBT per ml DIC work exceedingly well, although lesser or greater amounts are likely to work just as well. Most preferably, a lesser amount of HOBT is used, generally about 0.08
  • nitro-HOBT is used as a catalyst.
  • the methods of the present invention can also be used to load a non-linker- attached nucleoside (i.e., a nucleoside having a free 3' hydroxyl group) onto a column bearing a linker groug, e.g., a succinyl moiety.
  • a solid support to which a linker, most preferably succinic acid, has been attached is loaded by contacting it with a nucleoside having a free 3' hydroxyl group in the presence of DIC and HOBT.
  • the conditions for this reaction are the same as described herein for the loading of nucleosides bearing a 3' linker onto functionalized supports.
  • a solid support in which the amount of pyridine used as the reaction solvent and wash solvent is substantially reduced or eliminated.
  • pyridine need not be the main solvent in the loading reaction. Any solvent that dissolves the reactants but does not react itself can be used.
  • both acetonitrile and dichloromethane are suitable solvents. Acetonitrile is the most preferred solvent.
  • a mixture of pyridine with acetonitrile and or dichloromethane is used as the primary solvent for loading nucleosides.
  • a small amount of pyridine e.g., about 5%
  • the solvent is acetonitrile with very little (e.g., 5% or less) or no pyridine.
  • the present invention can be used with any functionalized solid support.
  • a number of such supports are known in the art. E.g., Pon in Methods in Molec. Biol, supra. We demonstrate below that both "TENTAGEL S” (Rapp Polymere, Tubingen, Germany)(a support in which polyethyleneglycol spacers are grafted on a gel-type support) and HLP (ABI, Foster City, CA) (a PEG-Polystyrene support) can be loaded with the current methods to extremely high densities.
  • CPG is the most preferred support for DNA synthesis.

Abstract

New methods of loading solid supports for oligonucleotide synthesis are presented. The new methods comprise coupling a succinylated nucleoside to a solid support using diisopropylcarbodiimide (DIC) as an activator and N-hydroxybenzotriazole (HOBT) as an acid catalyst. DIC is substantially cheaper than the currently used activating agent, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (DEC). Furthermore, in the preferred embodiment, when it is used in combination with HOBT, coupling is more efficient, requiring less nucleoside to achieve the same loading densities as in the prior art. The loading process is faster than prior art methods and the overall cost savings of about 43 % are realized.

Description

METHOD FOR LOADING SOLID SUPPORTS FOR NUCLEIC ACID SYNTHESIS
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to the field of oligonucleotide synthesis, and, more particularly, to methods of loading mononucleosides on a solid support. Description of the Related Art
Since Zamecnik and Stephenson, Proc. Natl. Acad. Sci. USA 75, 280-284 (1978) first demonstrated virus replication inhibition by synthetic ohgonucleotides, great interest has been generated in ohgonucleotides as therapeutic agents. In recent years the development of ohgonucleotides as therapeutic agents and as agents of gene expression modulation has gained great momentum. The greatest development has been in the use of so-called antisense ohgonucleotides, which form Watson-Crick duplexes with target RNAs. Agrawal, Trends in Biotechnology 10, 152-158 (1992), extensively reviews the development of antisense ohgonucleotides as antiviral agents. See also Uhlmann and Peymann, Chem. Rev. 90, 543 (1990).
Various methods have been developed for the synthesis of ohgonucleotides for such purposes. See generally, Methods in Molecular Biology, Vol. 20: Protocols for Ohgonucleotides and Analogs (S. Agrawal, Ed., Humana Press, 1993); Ohgonucleotides and Analogues: A Practical Approach (F. Eckstein, Ed., 1991); Uhlmann and Peyman, supra. Early synthetic approaches included
phosphodiester and phosphotriester chemistries. Khorana et al., J. Molec. Biol. 72, 209 (1972) discloses phosphodiester chemistry for oligonucleotide synthesis. Reese, Tetrahedron Lett. 34, 3143-3179 ( 1978), discloses phosphotriester chemistry for synthesis of ohgonucleotides and polynucleotides. These early approaches have largely given way to the more efficient phosphoramidite and H-phosphonate approaches to synthesis. Beaucage and Caruthers, Tetrahedron Lett. 22, 1859-1862 (1981), discloses the use of deoxynucleoside phosphoramidites in polynucleotide synthesis. Agrawal and Zamecnik, U.S. Patent No. 5,149,798 (1992), discloses optimized synthesis of ohgonucleotides by the H-phosphonate approach.
Both of these modern approaches have been used to synthesize ohgonucleotides having a variety of modified internucleotide linkages. Agrawal and Goodchild, Tetrahedron Lett. 28, 3539-3542 (1987), teaches synthesis of
oligonucleotide methylphosphonates using phosphoramidite chemistry. Connolly et al., Biochemistry 23, 3443 (1984), discloses synthesis of oligonucleotide phosphorothioates using phosphoramidite chemistry. Jager et al., Biochemistry 27, 7237 (1988), discloses synthesis of oligonucleotide phosphoramidates using phosphoramidite chemistry. Agrawal et al., Proc. Natl. Acad. Sci. USA 85, 7079-
7083 (1988), discloses synthesis of oligonucleotide phosphoramidates and phosphorothioates using H-phosphonate chemistry.
Solid phase synthesis of ohgonucleotides by the foregoing methods involves the same generalized protocol. Briefly, this approach comprises anchoring the 3'- most nucleoside to a solid support functionalized with amino and or hydroxyl moieties and subsequently adding the additional nucleosides in stepwise fashion. Desired internucleoside linkages are formed between the 3' functional group of the incoming nucleoside and the 5' hydroxyl group of the 5'-most nucleoside of the nascent, support-bound oligonucleotide. Oligonucleotide synthesis generally begins with coupling, or "loading," of the 3 '-most nucleoside of the desired oligonucleotide to a functionalized solid phase support. A variety of solid supports and methods for their preparation are known in the art. E.g. , Pon, "Solid-Phase Supports for Oligonucleotide Synthesis," in Methods in Molec. Biol. , Vol. 20,: Protocols for Ohgonucleotides and
Analogs, p. 465 (Agrawal, Ed., Humana Press, 1993). Generally, the functionalized support has a plurality of long chain alkyl amines (LCAA) on the surface that serve as sites for nucleoside coupling. Controlled pore glass (CPG) is the most widely used support. It consists of approximately 100-200 μm beads with pores ranging from a few hundred to a few thousand angstroms.
CPG supports are generally loaded by attaching a nucleoside-3'-succinate to the support through the succinyl group via an amide bond. Early efforts used dicyclohexylcarbo-diimide (DCC) to activate the nucleoside-3'-succinate. Activation was accomplished by converting the nucleoside-3'-succinate into the symmetrical anhydride (Sproat and Gait, in Oligonucleotide Synthesis: a Practical
Approach p. 83-115 (Gait, Ed., IRL Press, 1984)), or esterifying with p- nitrophenol (Atkinson and Smith, id. at 35-81; Koster et al., Tetrahedron 40, 103- 112 (1984)) or pentachlorophenol (Gough et al, Tetrahedron Lett. 22, 4177-4180 (1981); lerzek, Biochem. 25, 7840-7846 (1986)). Montserrat et al., Nucleosides & Nucleotides 12, 967 (1993) reported that
DCC and 1-hydoxybenzotriazole (HOBT) (used in equimolar amounts in a 14:1 dichloromethane/dimethylformamide solvent) resulted in higher loading densities than when DCC was used alone. The use of DCC suffers from a number of disadvantages, however. First, DCC is highly toxic. Second, loading was tedious and gave only moderate yields (50-75%). Third, the coupling reactions were lengthy, requiring 3-4 d to make the activated succinates and an additional 4-7 d to couple them to the CPG. And finally, loading values were quite variable, and optimum loading of 30-40 μmol/g was not always obtained.
Pon et al., Biotechniques 6, 768-775 (1988), improved on this method by employing l-(3-dimethylaminopropyl)-3-ethylcarbodiimide (DEC). Using this reagent along with a catalytic amount of dimethylaminopyridine (DMAP) in triethylamine/pyridine, Pon et al. observed direct coupling of the nucleoside-3'- succinate to the support. DEC, a smaller, less rigid carbodiimide (compared to DCC) was found to give much better results — loadings of up to 50 - 60 μmol/g could be obtained in 24 hours.
In an alternative procedure, Damha et al., Nucl. Acids Res. 18, 3813-3821 (1990), showed that loading could be accomplished by succinylating the LC AA of the solid support, thereby providing a carboxylic acid functional group, followed by direct attachment of a nucleoside by esterification with DEC and DMAP in pyridine.
Tong et al., J. Org. Chem 58, 2223 (1993), followed the approach of Damha et al., supra, and compared the efficiency of DCC, DEC, and DIC in loading 3' unprotected cytidine onto a succinylated CPG support under basic conditions. The reaction was conducted in the presence of DMAP in dry pyridine.
Loadings of 22 (DCC), 18 (DEC), and 30 (DIC) μmol/g were obtained. A major drawback of the current methods for loading solid support is that the main solvent is pyridine. Pyridine is toxic, has an obnoxious odor, and, therefore, is a work place and environmental hazard. In addition, DEC is costly, particularly when used in a large, production scale syntheses. Consequently, improved methods of column loading for oligonucleotide synthesis are desirable.
SUMMARY OF THE INVENTION
The present invention comprises new and improved methods of loading nucleosides onto a solid support for solid phase oligonucleotide synthesis. The methods of the present invention provide several advantages over prior art methods. First, they are more cost efficient. Cheaper, more efficient catalysts and activators used in the present invention result in cost savings as lesser amounts of both catalyst and mononucleoside reactant are required. Savings of approximately 43% have been observed for loading densities of about 70-80 μmol/g. Second, we are able to eliminate pyridine as a solvent, which not only effects cost savings, but improves the safety of the process, both to the worker and to the environment.
Concomitantly, fewer hazardous wastes are produced.
In a first aspect of the present invention, diisopropylcarbodiimide (DIC) is used as an activator in the acid catalyzed loading of succinylated mononucleoside. It has been unexpectedly found that the use of DIC in acid catalyzed loading is more effective than standard techniques using DEC; DIC is also more effective than DEC in acid catalyzed loading. DIC offers the further advantage of being cheaper per unit mass. DEC presently costs about $308/100 g while DIC costs about $97/100 g. In addition, DIC can be used in an amount that is about 20% that of DEC. In a second aspect of the present invention, 1-hydoxybenzotriazole (HOBT) is used in combination with DIC to catalyze linkage of a mononucleoside to an activated solid support. HOBT acts more efficiently and economically than other compounds such as N-hydroxysuccinimide (NHS), paratoluenesulfonic acid (pTSA), and trifluoroacteic acid (TFA). Loading densities approaching 120 μmol/g on controlled pore glass (CPG) solid support are readily obtained. Higher loading densities are also observed on other solid supports such as the "TENTAGEL" (Rapp Polymere) and "HLP" (ABI). Nitrobenzotriazole (NBT) acts as efficiently as HOBT, but is somewhat more expensive. In a the third aspect of the present invention, a method is presented for loading a non-linker-attached nucleoside (i.e., a nucleoside having a free 3' hydroxyl group) onto a solid support bearing a linker groug, e.g., a succinyl moiety. In this aspect of the invention, a solid support to which a linker has been attached is loaded by contacting it with a nucleoside having a free 3' hydroxyl group in the presence of DIC and HOBT.
In the fourth aspect of the present invention pyridine is eliminated as a solvent. Pyridine has generally been used in the loading process as a solvent and to dissolve and wash away all catalyst, unreacted starting materials, and reaction by-products. Because of pyridine's toxicity, its elimination from the loading process increases the safety of the process. In addition, fewer environmentally hazardous wastes are produced. We have found that acetonitrile can be used in place of pyridine without affecting loading efficiencies. Cost savings are also thereby realized. Another benefit provided by the methods of the present invention is the ability to adjust loading densities to any desired level, up to the maximum possible empirical value obtainable under optimal conditions. This is useful because equipment limitations (and/or other factors) may restrict the degree of loading to values substantially less than the empirical maximum.
The present methods can be used to load any nucleoside onto any functionalized solid support. The nucleoside may comprise any unmodified base
(e.g., A, T, C, G, or U) or modified base, and a modified or unmodified ribose moiety. Any solid support suitable for use in oligonucleotide synthesis can be used with the present methods.
The foregoing merely summarizes certain aspects of the present invention and is not intended, nor should it be construed, to limit the invention in any manner.
All patents and publications cited in this specification are hereby incorporated by reference in their entirety.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention comprises new methods for loading mononucleosides on a solid support. As used herein "loading" refers to the chemical linkage of a nucleoside (which will be the 3'-most nucleoside of the oligonucleotide to be synthesized) to a functional group on a solid support. The degree of loading is expressed in μmol monomer/g solid support. A "functional group" is a chemical moiety, such as an amino or hydroxyl moiety, capable of being joined to a nucleoside either directly or via a linker. A "functionalized support" is a support having such functional groups. Current methods of loading solid supports are slow, often taking up to about one week to load a controlled pore glass (CPG) support, and require about 90- 100 g (or about 0.15 mol) of DMT-protected succinylated monomer to load 500 g of CPG. Typical maximum loading densities are about 75 μmol/g. While loading in a 24 hour period has been reported, the loading densities are typically low. The methods presented herein substantially improve on these values. We have found that we are able to obtain loading densities in the range of 70 to 80 μmol/g using one third of the amount of DMT-protected succinylated monomer and that by increasing the amount of DMT-protected succinylated monomer, activator, and catalyst, loading densities of about 120 μmol/g are easily obtained on CPG. We have observed higher loading densities on other supports having a greater concentration of functional groups. In addition to achieving higher loading densities, the new methods are faster as well, allowing complete loading of the column (with high loading density) in just two days. Thus, use of the methods disclosed herein will substantially reduce costs and time.
The new methods disclosed herein are also significantly less hazardous for the worker and safer for the environment. Pyridine is currently used as a reaction solvent and, alone or in combination with other solvents, to wash away unreacted reactants, catalyst, and unwanted reaction by-products. We have found that the amount of pyridine can be reduced to about 5% in acetonitrile or eliminated completely. Because pyridine is toxic and has an obnoxious odor, the present methods are less hazardous than the prior art methods.
The present methods also require lesser amounts of reagents, resulting in lesser costs and amounts of waste. We have found that column loading densities in the range of about 70-80 μmol/g can be attained using less than about 3 x 10° mol of nucleoside per 25 g of CPG. Thus, the current methods provide additional cost savings by these means as well. Overall, savings of about 43% are realized with the new methods for loading densities in the range of about 70-80 μmol/g. The present invention provides methods of loading a functionalized solid support for oligonucleoside synthesis comprising contacting the functionalized solid support with a solvent, diisopropylcarbodiimide, and a nucleoside having a 3' linker group attached at a pH of less than 7.0.
In the first embodiment of the invention, diisopropylcarbodiimide (DIC) is used as an activator for the acid catalyzed loading of nucleoside-3 '-succinates. The activator forms an intermediate with the terminal carboxylic acid moiety of the nucleoside-3'-succinate, rendering it susceptible to nucleophilic attack by a support- bound amino functional group. It has been unexpectedly found that DIC in the presence of 1-hydroxybenzotirazole (HOBT) is more effective than DEC at activating the succinyl carboxylic acid moiety. Under ideal conditions, wherein the coupling of the nucleoside-3'-succinate to the solid support is 100% complete, 1 equivalent of DIC is required to couple 1 equivalent of nucleoside-3'-succinate to the support. DIC is moisture sensitive, however, and therefore, in general, more than 1 equivalent is required. This will not detract appreciably from the cost benefit of using DIC since it is substantially cheaper than DEC. We have found that about 2.5 to 3.0 eq of DIC per 1 eq of mononucleoside succinate results in excellent loading, routinely yielding loading densities of about 75 to about 85 μmol/g.
In the second embodiment of the invention, HOBT is used to catalyze DIC activated loading. Experiments using pyridine as a solvent (presented infra) demonstrate that HOBT is a more effective than other compounds such as N- hydroxysuccinimide (NHS), paratoluenesulfonic acid (pTSA), and trifluoroacetic acid (TFA). Our experiments demonstrate that the use of HOBT results in loading densities ranging from 30 to 100% greater than those attained using NHS, pTSA, and TFA. The amount of HOBT is not critical; it should be sufficient to catalyze the reaction. We have found that about 0.08 to about 0.16 g HOBT per ml DIC work exceedingly well, although lesser or greater amounts are likely to work just as well. Most preferably, a lesser amount of HOBT is used, generally about 0.08
g- In another aspect of this embodiment, nitro-HOBT is used as a catalyst.
Our experiments show that catalysis with nitro-HOBT results in essentially equivalent loading densities as compared to when HOBT is used. Nitro-HOBT is used in the amount as described above for HOBT.
The methods of the present invention can also be used to load a non-linker- attached nucleoside (i.e., a nucleoside having a free 3' hydroxyl group) onto a column bearing a linker groug, e.g., a succinyl moiety. Accordingly, in a third embodiment of the present invention, a solid support to which a linker, most preferably succinic acid, has been attached is loaded by contacting it with a nucleoside having a free 3' hydroxyl group in the presence of DIC and HOBT. The conditions for this reaction are the same as described herein for the loading of nucleosides bearing a 3' linker onto functionalized supports.
In a fourth embodiment of the present invention, methods of loading a solid support are presented in which the amount of pyridine used as the reaction solvent and wash solvent is substantially reduced or eliminated. We have found that pyridine need not be the main solvent in the loading reaction. Any solvent that dissolves the reactants but does not react itself can be used. We have found that both acetonitrile and dichloromethane are suitable solvents. Acetonitrile is the most preferred solvent. In one aspect of this embodiment, a mixture of pyridine with acetonitrile and or dichloromethane is used as the primary solvent for loading nucleosides. A small amount of pyridine (e.g., about 5%) may be used to ensure a minimal amount of detritylation, but is not required. Accordingly, in another aspect of this embodiment, no pyridine is used. Because of the reduced costs, in the most preferred embodiment the solvent is acetonitrile with very little (e.g., 5% or less) or no pyridine.
The present invention can be used with any functionalized solid support. A number of such supports are known in the art. E.g., Pon in Methods in Molec. Biol, supra. We demonstrate below that both "TENTAGEL S" (Rapp Polymere, Tubingen, Germany)(a support in which polyethyleneglycol spacers are grafted on a gel-type support) and HLP (ABI, Foster City, CA) (a PEG-Polystyrene support) can be loaded with the current methods to extremely high densities. CPG is the most preferred support for DNA synthesis.
While the results presented below were obtained using succinylated thymidine monomer, those skilled in the art will appreciate that any suitably protected nucleoside monomer (naturally occurring or modified) can be used with the present methods. Dimer blocks and other multinucleoside synthons can also be loaded according to the methods of the present invention. In addition, although succinic acid is the preferred linker, any suitable linker can be used. Such a linker will preferably have a free carboxyl group that a support-bound amino group can attack to form an amide bond, thereby binding the linker and its attached nucleoside to the support. Examples of alternative linkers are disclosed by Pon in Methods in Molec. Biol, supra.
The following Examples are intended for illustrative purposes and are not intended, nor should they be construed, as limiting the invention in any way.
EXAMPLES
Example 1
Standard Method of Loading of DMT-dT-Succinic Acid on Controlled Pore
Glass 500 g of CPG (Schott, Hozheim, Germany) (particle size: 100-130 μm; pore size: D50: 41.6nm), 6.1 g of dimethylamino pyridine (Aldrich, Milwaukee, WI), 50 g of triethylamine (Aldrich), and 100 g of ethyl-3-(3-dimethylamino propyl) carbodiimide (DEC, mol. wt. 191.7) (Sigma, St. Louis, MO) were placed in a 5 1 Schott bottle and hand shaken for 20 minutes. 60 g of DMT-dT-succinic acid (Monomer Sciences , Huntsville, AL) was added and the bottle capped and shaken in an orbital shaker at 160 rpm for 18 hours.
A small analytical sample of the resin was withdrawn from the Schott bottle, successively washed with pyridine (3 x 5 ml) (Baxter, Muskegon, MI), methanol (3 x 5 ml) (Baxter), and methylene chloride (3 x 5 ml ) (EM Science, Cincinnati, OH) successively, and dried in vacuo.
Approximately 20 mg of dry resin was weighed, 200 μl perchloric acid/ethanol (6:4) was added, and the resulting solution diluted to 100 ml with methylene chloride. The absorbance was measured at 498 nm. The same procedure was repeated on a second analytical sample and the average loading value calculated using Beer's law with a molar absorption coefficient of 70 l/(mol cm) for DMT. A loading value of 66.7 μmol/g was obtained.
An additional 20.0 g of DMT-dT-succinic acid was added to the Schott bottle and the mixture shaken for 18 hours at ambient temperature. Another analytical sample was removed and worked-up as described above. The absorbance of the sample was measured and a loading value of 66.5 μmol/g obtained.
Another 20.0 g of DMT-dT-succinic acid was added to the Schott bottle and the mixture shaken for 18 hours at ambient temperature. A third analytical sample was removed and worked-up as described above. The absorbance of the sample was measured and a loading value of 69.6 μmol/g obtained.
The mixture remaining in the Schott bottle was filtered and the resin washed with pyridine (3 x 1 1). The dry solid was transferred to a Schott bottle and Cap A (1.01 of acetic anhydride in tetrahydrofuran) (Cruachem, Linvingstone, United Kingdom) and Cap B (1.5 1 of N-methylimidzole, pyridine in tetrahydrofuran) (MiUipore, Bedford, MA) were added. The mixture was shaken for 18 hours at ambient temperature. The solid (CPG-T) was filtered and successively washed with methanol (3 x 1 1) and methylene chloride (3 x 1 1) and dried in vacuo to yield 502.5 g. The resin was subjected to the same procedure described above for each of the small samples. A loading value of 71.4 μmol/g was obtained.
Example 2 New Method of Loading DMT-dT-Succinic Acid on Controlled Pore Glass 250.0 g of CPG (Schott), 0.8 g of hydroxybenzotriazole (mol. wt. 135.13)
(Aldrich), and 10 ml of 1,3-diisopropylcarbodiimide (DIC, mol. wt. 126.20, density = 0.806 g/ml) (Aldrich) were mixed with 50 ml of pyridine (Baxter) and
1 1 of acetonitrile (Baxter) in a 2 1 Schott bottle and shaken for 20 minutes. 15 g of DMT-T-succinic acid (mol. wt. 644) (Monomer Sciences) were added, the bottle stoppered and shaken in an orbital shaker at a rate of 180 rpm for 16 hours.
A small analytical sample of the resin was withdrawn from the Schott bottle and washed with 5% pyridine in acetonitrile (3 x 5 ml), methanol (3 x 5 ml), and methylene chloride (3 x 5 ml) successively and dried under a stream of in vacuo.
Approximately 20 mg of the dry resin were weighed and 200 ml perchloric acid/ ethanol (6:4) added. The solution was diluted to 70 ml with methylene chloride and the absorbance measured at 498 nm. The entire procedure was repeated and the average value of the absorbencies used to calculate the loading. The loading was calculated as above. An average loading value of 78.0 μmol/g was obtained.
The remaining solution in the Schott bottle was filtered and washed with 5% pyridine in acetonitrile (3 x 500 ml). Dry solid was transferred to a Schott bottle and Cap A (500 ml) and Cap B (750 ml) (Cap A and Cap B were as described above) were added and the mixture shaken for 16 hours at ambient temperature. The solid (CPG-T) was filtered, washed successively with methanol (3 x 500 ml) and then methylene chloride (3 x 500 ml), and dried in vacuo to yield 250 g of CPG-T. The loading value, 78 μmol/g, was calculated as described
above. This entire procedure was repeated, substituting varying amounts of the reactants and using several catalysts and supports. The results are present in Table 1.
From the foregoing it will be appreciated that although specific embodiments of the present invention have been described herein for the purposes of illustration, various modification may be made without deviating from the spirit or scope of the invention.
Figure imgf000018_0001

Claims

What is claimed is:
1. A method of loading a functionalized solid support for oligonucleoside synthesis comprising simultaneously contacting the functionalized solid support with diisopropylcarbodiimide, nucleoside having a 3' linker group attached, and an acid catalyst.
2. The method of claim 1 wherein the acid catalyst is N- hydroxybenzotriazole or nitrohydroxybenzotriazole, or a combination thereof.
3. The method of claim 2 wherein the solid support is CPG and less than about 3 x 103 mol of nucleoside is used per 25 g of CPG.
4. The method of claim 3 wherein about 2 to about 3 moles of diisopropylcarbodiimide are used per mole of nucleoside.
5. The method of claim 4 wherein the amount of N- hydroxybenzotriazole or nitrohydroxybenzotriazole, or combination thereof is about
0.1 times that of the diisopropylcarbodiimide.
6. The method of claim 2 wherein the solvent comprises about 5% or less pyridine.
7. The method of claim 6 wherein the solid support is CPG and less than about 3 x 103 mol of nucleoside is used per 25 g of CPG.
8. The method of claim 7 wherein about 2 to about 3 moles of diisopropylcarbodiimide are used per mole of nucleoside.
9. The method of claim 8 wherein the amount of N- hydroxybenzotriazole or nitrohydroxybenzotriazole, or combination thereof is about 0.1 that of the diisopropylcarbodiimide.
10. The method of claim 2 wherein the solvent contains no pyridine.
11. The method of claim 10 wherein the solid support is CPG and less than about 3 x 10"3 mol of nucleoside is used per 25 g of CPG.
12. The method of claim 11 wherein about 2 to about 3 moles of diisopropylcarbodiimide are used per mole of nucleoside.
13. The method of claim 12 wherein the amount of N- hydroxybenzotriazole or nitrohydroxybenzotriazole, or combination thereof is about 0.1 that of the diisopropylcarbodiimide.
14. A method of loading a functionalized solid support for oligonucleoside synthesis comprising simultaneously contacting a functionalized solid support having a linker moiety with diisopropylcarbodiimide, nucleoside having a free 3' hydoxy group, and an acid catalyst.
15. The method of claim 14 wherein the acid catalyst is N- hydroxybenzotriazole or nitrohydroxybenzotriazole, or a combination thereof.
16. The method of claim 15 wherein the functionalized solid support is CPG.
17. The method of claim 16 wherein the solid support is CPG and less than about 3 x 10'3 mol of nucleoside is used per 25 g of CPG.
18. The method of claim 19 wherein about 2 to about 3 moles of diisopropylcarbodiimide are used per mole of nucleoside.
19. The method of claim 18 wherein the amount of N- hydroxybenzotriazole or nitrohydroxybenzotriazole, or combination thereof is about 0.1 times that of the diisopropylcarbodiimide.
20. The method of claim 15 wherein the solvent comprises about 5% or less pyridine.
21. The method of claim 20 wherein the solid support is CPG and less than about 3 x 10° mol of nucleoside is used per 25 g of CPG.
22. The method of claim 21 wherein about 2 to about 3 moles of diisopropylcarbodiimide are used per mole of nucleoside.
23. The method of claim 22 wherein the amount of N- hydroxybenzotriazole or nitrohydroxybenzotriazole, or combination thereof is about 0.1 that of the diisopropylcarbodiimide.
24. The method of claim 15 wherein the solvent contains no pyridine.
25. The method of claim 24 wherein the solid support is CPG and less than about 3 x 10° mol of nucleoside is used per 25 g of CPG.
26. The method of claim 25 wherein about 2 to about 3 moles of diisopropylcarbodiimide are used per mole of nucleoside.
27. The method of claim 26 wherein the amount of N- hydroxybenzotriazole or nitrohydroxybenzotriazole, or combination thereof is about 0.1 that of the diisopropylcarbodiimide.
PCT/US1995/012196 1994-09-23 1995-09-22 Method for loading solid supports for nucleic acid synthesis WO1996009314A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU37242/95A AU3724295A (en) 1994-09-23 1995-09-22 Method for loading solid supports for nucleic acid synthesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/311,156 US5554744A (en) 1994-09-23 1994-09-23 Method for loading solid supports for nucleic acid synthesis
US08/311,156 1994-09-23

Publications (2)

Publication Number Publication Date
WO1996009314A2 true WO1996009314A2 (en) 1996-03-28
WO1996009314A3 WO1996009314A3 (en) 1996-05-30

Family

ID=23205659

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012196 WO1996009314A2 (en) 1994-09-23 1995-09-22 Method for loading solid supports for nucleic acid synthesis

Country Status (4)

Country Link
US (1) US5554744A (en)
AU (1) AU3724295A (en)
CA (1) CA2200552A1 (en)
WO (1) WO1996009314A2 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979728B2 (en) * 1998-05-04 2005-12-27 Baylor College Of Medicine Articles of manufacture and methods for array based analysis of biological molecules
US6048695A (en) * 1998-05-04 2000-04-11 Baylor College Of Medicine Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
EP1356088A2 (en) * 2000-06-07 2003-10-29 Baylor College of Medicine Compositions and methods for array-based nucleic acid hybridization
WO2003020978A1 (en) * 2001-09-01 2003-03-13 Samsung Electronics Co., Ltd. Method for manufacturing hydrogel biochip by using star-like polyethylene glycol derivative having epoxy group
JP2005519634A (en) * 2001-10-12 2005-07-07 スペクトラル ジェノミクス、インク. Nucleic acid compositions and arrays and methods using them
US7439346B2 (en) 2001-10-12 2008-10-21 Perkinelmer Las Inc. Nucleic acids arrays and methods of use therefor
WO2003042697A1 (en) * 2001-11-14 2003-05-22 Genospectra, Inc. Biochemical analysis system with combinatorial chemistry applications
US20030124542A1 (en) * 2001-12-28 2003-07-03 Spectral Genomics, Inc. Methods for mapping the chromosomal loci of genes expressed by a cell
CA2475003A1 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US20050009051A1 (en) * 2002-09-27 2005-01-13 Board Of Regents, The University Of Texas Diagnosis of mould infection
US20040248798A1 (en) 2003-02-14 2004-12-09 Peter Sutovsky Contraceptive methods and compositions related to proteasomal interference
CA2557841A1 (en) * 2004-02-27 2005-09-09 President And Fellows Of Harvard College Polony fluorescent in situ sequencing beads
EP2471921A1 (en) 2004-05-28 2012-07-04 Asuragen, Inc. Methods and compositions involving microRNA
ES2345993T3 (en) 2004-09-14 2010-10-07 The Regents Of The University Of Colorado, A Body Corporate METHOD FOR TREATMENT WITH BUCINDOLOL BASED ON GENETIC ADDRESSING.
EP2302054B1 (en) 2004-11-12 2014-07-16 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US20090264635A1 (en) 2005-03-25 2009-10-22 Applera Corporation Methods and compositions for depleting abundant rna transcripts
WO2008036765A2 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
BRPI0906429B1 (en) 2008-01-10 2021-08-03 Research Development Foundation METHOD OF IDENTIFYING AN E. CHAFFEENSIS INFECTION IN AN INDIVIDUAL, USE OF ONE OR MORE SYNTHETIC POLYPEPTIDE AND KIT
MX2010008168A (en) 2008-01-25 2011-02-24 P53 Inc P53 biomarkers.
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
US20100047876A1 (en) * 2008-08-08 2010-02-25 President And Fellows Of Harvard College Hierarchical assembly of polynucleotides
AU2009313255B2 (en) 2008-11-07 2014-08-07 Research Development Foundation Compositions and methods for the inhibition of Cripto/GRP78 complex formation and signaling
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
EP2379720B1 (en) 2009-01-20 2016-08-17 Alona Zilberberg Mir-21 promoter driven targeted cancer therapy
US20110045080A1 (en) * 2009-03-24 2011-02-24 William Marsh Rice University Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
WO2011008530A2 (en) 2009-06-29 2011-01-20 Luminex Corporation Chimeric primers with hairpin conformations and methods of using same
CA2771769C (en) 2009-08-28 2019-10-29 Research Development Foundation Urocortin 2 analogs and uses thereof
US9512481B2 (en) 2009-09-11 2016-12-06 The Regents Of The University Of Colorado, A Body Corporate Polymorphisms in the PDE3A gene
EP2515899B1 (en) 2009-12-23 2016-05-25 ARCA biopharma, Inc. Methods and compositions for cardiovascular diseases and conditions
WO2011099664A1 (en) 2010-02-12 2011-08-18 엠앤디(주) Probe for hpv genotype diagnosis and analysis method thereof
EP2538943B1 (en) 2010-02-25 2016-03-30 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
WO2011108930A1 (en) 2010-03-04 2011-09-09 Interna Technologies Bv A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
WO2011128886A1 (en) 2010-04-12 2011-10-20 Ramot At Tel Aviv University Ltd. A micro-rna for cancer diagnosis, prognosis and therapy
WO2011156588A1 (en) 2010-06-09 2011-12-15 Dana-Farber Cancer Institute, Inc. A mek 1 mutation conferring resistance to raf and mek inhibitors
NZ719520A (en) 2010-07-06 2017-07-28 Int Tech Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
CA2814049C (en) 2010-10-08 2021-07-13 President And Fellows Of Harvard College High-throughput single cell barcoding
ES2629890T3 (en) 2010-11-17 2017-08-16 Interpace Diagnostics, Llc miRNA as biomarkers to distinguish between benign and malignant thyroid neoplasms
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
MY165507A (en) 2011-02-03 2018-03-28 Mirna Therapeutics Inc Synthetic mimics of mir-34
EP2670849A1 (en) 2011-02-03 2013-12-11 Mirna Therapeutics, Inc. Synthetic mimics of mir-124
WO2013037065A1 (en) 2011-09-13 2013-03-21 Ottawa Hospital Research Institute Microrna inhibitors
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
US10501791B2 (en) 2011-10-14 2019-12-10 President And Fellows Of Harvard College Sequencing by structure assembly
WO2013063519A1 (en) 2011-10-26 2013-05-02 Asuragen, Inc. Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
EP3369818B1 (en) 2011-12-22 2021-06-09 InteRNA Technologies B.V. Mirna for treating head and neck cancer
WO2013184754A2 (en) 2012-06-05 2013-12-12 President And Fellows Of Harvard College Spatial sequencing of nucleic acids using dna origami probes
CN104662544B (en) 2012-07-19 2018-08-03 哈佛大学校长及研究员协会 The method for storing information using nucleic acid
EP2897633B1 (en) 2012-09-18 2020-01-01 UTI Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
US20140100124A1 (en) 2012-10-04 2014-04-10 Asuragen, Inc. Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
US9476089B2 (en) 2012-10-18 2016-10-25 President And Fellows Of Harvard College Methods of making oligonucleotide probes
EP2917348A1 (en) 2012-11-06 2015-09-16 InteRNA Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
WO2014116721A1 (en) 2013-01-22 2014-07-31 The Arizona Board Of Regents For And On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
US10398661B2 (en) 2013-02-28 2019-09-03 The Board Of Regents Of The University Of Texas System Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers
US10138509B2 (en) 2013-03-12 2018-11-27 President And Fellows Of Harvard College Method for generating a three-dimensional nucleic acid containing matrix
EP2970909A4 (en) 2013-03-15 2017-02-15 The University of Chicago Methods and compositions related to t-cell activity
BR112016007391A2 (en) 2013-10-03 2017-08-01 Oklahoma Med Res Found biomarkers of activity, intensity and acute phase of systemic lupus erythematosus disease
US10028902B2 (en) 2013-11-08 2018-07-24 Baylor Research Institute Nuclear localization of GLP-1 stimulates myocardial regeneration and reverses heart failure
US11421229B2 (en) 2015-02-20 2022-08-23 Baylor College Of Medicine p63 inactivation for the treatment of heart failure
US20190177391A1 (en) 2016-03-31 2019-06-13 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
US10927379B2 (en) 2016-09-16 2021-02-23 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
US11497762B2 (en) 2017-11-03 2022-11-15 Interna Technologies B.V. MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
CN116585308A (en) 2018-05-25 2023-08-15 Arca生物制药有限公司 Methods and compositions relating to bucindolol treatment of atrial fibrillation
WO2022097157A2 (en) 2020-11-09 2022-05-12 1E Therapeutics, Ltd. Catalytic sequence based methods of treating or preventing bacterial infections
WO2022144883A2 (en) 2020-12-28 2022-07-07 1E Therapeutics, Ltd. P21 mrna targeting dnazymes
AU2021411103A1 (en) 2020-12-28 2023-07-13 1E Therapeutics, Ltd. P21 mrna target areas for silencing
EP4320445A1 (en) 2021-04-08 2024-02-14 Joslin Diabetes Center, Inc. Methods of diagnosing and predicting renal decline
WO2024015766A1 (en) 2022-07-12 2024-01-18 Topogene Inc. Scalable, submicron-resolution replication of dna arrays

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013080A1 (en) * 1990-02-20 1991-09-05 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
US5204455A (en) * 1989-06-15 1993-04-20 Froehler Brian C Monomethoxytrityl protected oligonucleotides bound to a solid support

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149798A (en) * 1989-04-06 1992-09-22 Worcester Foundation For Experimental Biology Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204455A (en) * 1989-06-15 1993-04-20 Froehler Brian C Monomethoxytrityl protected oligonucleotides bound to a solid support
WO1991013080A1 (en) * 1990-02-20 1991-09-05 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. ORG. CHEM., vol. 58, 1993 pages 2223-31, J.M. LAWLOR ET AL. 'The synthesis of oligonucleotide-polyamide conjugate molecules suitable as PCR primers' cited in the application *
NUCLEOSIDES, NUCLEOTIDES, vol. 12, 1993 pages 967-71, E. PEDROSO ET AL. 'Predictable and reproducible yields in the anchoring of DMT-nucleoside-succinates to highly loaded aminoalkyl-polystyrene resins' cited in the application *
SYNTH. COMMUN., vol. 25, no. 22, 1995 pages 3671-9, N. BHONGLE AND J.Y. TANG 'A convenient and practical method for dervatization of solid supports for nucleic acid synthesis ' *
TETRAHEDR. LETT., vol. 34, 1993 pages 8169-72, A. GUZAEV ET AL. 'Synthesis of 3'-functionalized oligonucleotides on a single solid support' *

Also Published As

Publication number Publication date
AU3724295A (en) 1996-04-09
CA2200552A1 (en) 1996-03-28
US5554744A (en) 1996-09-10
WO1996009314A3 (en) 1996-05-30

Similar Documents

Publication Publication Date Title
US5554744A (en) Method for loading solid supports for nucleic acid synthesis
US4659774A (en) Support for solid-phase oligonucleotide synthesis
AU712779C (en) Method for solution phase synthesis of oligonucleotides
EP1343802B1 (en) Process for the preparation of oligonucleotides
JP3684182B2 (en) New reagents for labeling nucleic acids
JP2001505543A (en) Solid phase synthesis method
WO1997031009A1 (en) Solid phase synthesis of oligonucleotide n3'→p5' phosphoramidates
AU6022398A (en) Method for solution phase synthesis of oligonucleotides and peptides
Muller et al. Current strategies for the synthesis of RNA
US5668268A (en) Passivated polymer supports for nucleic acid synthesis
JP3754449B2 (en) Solid support reagent for the synthesis of 3 'nitrogen containing polynucleotides
US20040215010A1 (en) Universal solid supports for solid phase oligosynthesis and methods for their preparation and use
US20030195351A1 (en) Methods for the integrated synthesis and purification of oligonucleotides
WO1998016540A1 (en) Improved coupling activators for oligonucleotide synthesis
US20030194741A1 (en) Combinatorial protecting group strategy for multifunctional molecules
CN110891961B (en) Improved process for the preparation of imaelstat
Bhongle et al. A convenient and practical method for derivatization of solid supports for nucleic acid synthesis
US7705136B2 (en) Synthesis of 3′-, or 5′-, or internal methacrylamido-modified oligonucleotides
CN114014902B (en) Dimeric nucleotide and synthesis method thereof
US20040010081A1 (en) Novel strategy for synthesizing polymers in surfaces
Tetzlaff et al. Synthesis and hydrolytic stability of 5′-aminoacylated oligouridylic acids
TW202300504A (en) Universal linker reagents for dna synthesis
AU703509C (en) Solid phase synthesis of oligonucleotide N3'-P5' phosphoramidates
Wang et al. Affinity chromatography using enzymatically synthesized nucleotide-containing DNA binding polymers
EP0839829A2 (en) Universal solid support oligonucleotide reagents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2200552

Country of ref document: CA

Ref country code: CA

Ref document number: 2200552

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 809026

Date of ref document: 19970714

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase